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A limited number of biomarkers in the central and peripheral systems which are known
may be useful for diagnosing major depressive disorders and predicting the effectiveness
of antidepressant (AD) treatments. Since 60% of depressed patients do not respond
adequately to medication or are resistant to ADs, it is imperative to delineate more
accurate biomarkers. Recent clinical studies suggest that β-arrestin 1 levels in human
mononuclear leukocytes may be an efﬁcient biomarker. If potential biomarkers such
as β-arrestin 1 could be assessed from a source such as peripheral blood cells, then
they could be easily monitored and used to predict therapeutic responses. However,
no previous studies have measured β-arrestin 1 levels in peripheral blood mononuclear
cells (PBMCs) in anxious/depressive rodents. This study aimed to develop a method to
detect β-arrestin protein levels through immunoblot analyses of mouse PBMCs isolated
from whole blood. In order to validate the approach, β-arrestin levels were then compared
in naïve, anxious/depressed mice, and anxious/depressed mice treated with a selective
serotonin reuptake inhibitor (ﬂuoxetine, 18 mg/kg/day in the drinking water). The results
demonstrated that mouse whole blood collected by submandibular bleeding permitted
isolation of enough PBMCs to assess circulating proteins such as β-arrestin 1. β-Arrestin 1
levels were successfully measured in healthy human subject and naïve mouse PBMCs.
Interestingly, PBMCs from anxious/depressed mice showed signiﬁcantly reduced β-
arrestin 1 levels. These decreased β-arrestin 1 expression levels were restored to normal
levels with chronic ﬂuoxetine treatment. The results suggest that isolation of PBMCs from
mice by submandibular bleeding is a useful technique to screen putative biomarkers of the
pathophysiology of mood disorders and the response to ADs. In addition, these results
conﬁrm that β-arrestin 1 is a potential biomarker for depression.
Keywords: peripheral blood mononuclear cells, β-arrestin 1, anxiety, depression, mouse models, fluoxetine,
biomarkers
INTRODUCTION
Elucidation of the neurobiological bases of depression and anx-
iety are signiﬁcant challenges for today’s society. Mood dis-
orders impact 7% of the world’s population and rank among
the top 10 causes of disability (Kessler et al., 2005). Selective
serotonin reuptake inhibitors (SSRIs) and serotonin and nora-
drenaline reuptake inhibitors (SNRIs) are the most commonly
prescribed antidepressant (AD) drugs for major depressive disor-
ders (MDD; Samuels et al., 2011). However, key questions about
the molecular and cellular mechanisms underlying the effects
of ADs remain unanswered. Approximately 60% of depression
patients do not respond adequately or are resistant to these drugs
(Samuels et al., 2011). Therefore, there are clear beneﬁts of hav-
ing valid, reliable, selective, and feasible biomarkers for MDD.
Several studies have reported genome-wide expression changes
associatedwithADresponses inMDD(Iga et al., 2007a,b; Belzeaux
et al., 2010; Lakhan et al., 2010; Mamdani et al., 2011). However,
candidate biomarkers that can accurately predict AD responses
must be identiﬁed. While there are currently no speciﬁc mark-
ers that are considered “gold standards,” a few candidates have
emerged. Peripheral/serum brain-derived neurotrophic factor
(BDNF), insulin-like growth factor 1 (IGF-1), and cytokines may
serve as biomarkers of MDD and treatment response (for review,
see Schmidt et al., 2011).
Recently, a substantial body of evidence indicates that β-
arrestins (β-arrestin 1 and 2), proteins that regulate G protein
receptor coupling, play major roles in the pathophysiology of
mood disorders and in the mechanisms underlying AD actions
(Avissar et al., 2004; Schreiber andAvissar, 2004; Matuzany-Ruban
et al., 2005; Beaulieu et al., 2008; David et al., 2009; Schreiber
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et al., 2009; Golan et al., 2010). The β-arrestin-signaling cascade
has recently gained attention as a potential pre-clinical/clinical
bridging biomarker for depressive states and treatment effects.
In naïve rats, SSRI, SNRI, and non-selective reuptake inhibitor
ADs signiﬁcantly elevate β-arrestin 1 levels in the cortex and
the hippocampus (Avissar et al., 2004; Beaulieu and Caron, 2008;
Beaulieu et al., 2008; David et al., 2009). Similarly, β-arrestin 1
expression is decreased in the hypothalamus and hippocampus in
anxious/depressed mice exposed to glucocorticoid elevation, and
is restored by chronic ﬂuoxetine treatment (David et al., 2009).
Moreover, β-arrestin 1 and 2 signaling is involved in mediating the
response to ﬂuoxetine and lithium (Beaulieu et al., 2008; David
et al., 2009).
Clinical data from Avissar et al. (2004) suggest that β-arrestin
1 mRNA and protein levels are highest in peripheral blood leuko-
cytes of MDD patients. Therefore, β-arrestin 1 may be a putative
candidate biochemical marker in clinical practice for depressive
pathophysiology and the response toADs (for review, see Schreiber
et al., 2009). β-Arrestin mRNA levels and β-arrestin 1 protein lev-
els in mononuclear leukocytes of untreated patients with MDD
are lower than the levels found in healthy subjects. Furthermore,
reduced levels of β-arrestin 1 protein and mRNA are signiﬁcantly
correlated with the severity of depressive symptoms (Avissar et al.,
2004; Schreiber et al., 2009). However, the low β-arrestin 1 protein
and mRNA levels are alleviated by AD treatment. Therefore, these
low levels can predict clinical improvement (Avissar et al., 2004;
Golan et al., 2010).
These clinical data suggest that assessment of β-arrestin 1 levels
may prove useful for diagnosing depression with high sensitiv-
ity and speciﬁcity (Golan et al., 2013). This hypothesis must ﬁrst
be validated in animal models of anxiety–depression. Most of
the current understandings of mood disorders and AD activities
are based on studies performed on animal models of anxiety–
depression (Belzung and Lemoine, 2011). No animal studies have
investigatedwhether β-arrestin 1 protein levels in peripheral blood
mononuclear cells (PBMCs) area marker of the pathophysiology
of depression and the AD response. However, if PBMCs can be
successfully used to deﬁne biomarkers, they provide a system of
circulating cells that can be easily collected from patients and
monitored to predict therapeutic responses.
In this study, we developed a method to measure and assess cir-
culating proteins (such as β-arrestin 1 in PBMCs) that are collected
through submandibular bleeding from unanesthetized animals.
Furthermore, we examined whether changes in β-arrestin 1 levels
in mouse PBMCs were observed in a model of anxiety/depression
(David et al., 2009; Guilloux et al., 2011; Rainer et al., 2012b), and
whether these levels could be corrected by chronic treatment with
the SSRI ﬂuoxetine.
EXPERIMENTAL PROCEDURES
SUBJECTS
Adult male C57BL/6Ntac mice were purchased from Taconic
Farms (Lille Skensved, Denmark). All mice were 7–8 weeks old,
weighed 23–25 g at the beginning of the treatment and were main-
tained on a 12L:12D schedule (lights on at 0600 hours). The mice
were group-housed with each cage containing ﬁve animals. Food
and water were provided ad libitum. All testing were conducted
in compliance with the laboratory animal care guidelines and
with protocols approved by the Institutional Animal Care and
Use Committee (Council directive # 87-848, October 19, 1987,
Ministère de l’Agriculture et de la Forêt, Service Vétérinaire de la
Santé et de la Protection Animale, permissions # 92-256B to Denis
J. David).
DRUGS
Corticosterone (4-pregnen-11b-DIOL-3 20-DIONE 21-hemi-
succinate from Sigma (Sigma-Aldrich, Saint-Quentin-Fallavier,
France) was dissolved in 0.45% hydroxypropyl-β-cyclodextrin
(Sigma-Aldrich, Saint-Quentin-Fallavier, France). Fluoxetine
hydrochloride (18mg/kg/day in thedrinkingwater)waspurchased
from Anawa Trading (Zurich, Switzerland).
ISOLATION OF HUMAN AND MOUSE PERIPHERAL BLOOD
MONONUCLEAR CELLS
Collection of human blood and isolation of peripheral blood
mononuclear cells
Peripheral blood mononuclear cells were puriﬁed from 7.5 ml
of human whole circulating blood obtained from Etablissement
Français du Sang (Ivry-Sur-Seine, France) through density cen-
trifugation (850 g at 20◦C for 20 min) using a Ficoll gradient
(PAA Laboratories GmbH,Pashing,Austria; Figure 1A). This cen-
trifugation separated lymphocytes, monocytes, and plasma. The
PBMC layerswere carefully removed from the tube and transferred
to a new 50 ml conical tube. The PBMCs were then washed twice
(1 min each) with 1× phosphate-buffered saline (PBS)/fetal calf
serum (FCS, 2%). After centrifugations (150 g at 20◦C for 7 min),
the cells were resuspended in the appropriate volume of 1× PBS.
ThehumanPBMCswere then recoveredwith a ﬁnal centrifugation
(1,000 g at 4◦C for 5 min) and were stored at −80◦C.
Collection of mouse blood and isolation of peripheral blood
mononuclear cells
Blood was collected from unanesthetized mice as previously
described (Golde et al., 2005; Joslin, 2009). In compliance with
the laboratory animal care guidelines, approximately 0.4 ml of
blood per mouse was collected in K3EDTA tubes with a sub-
mandibular bleeding procedure. Five millimeters point size sterile
lancets (MediPoint, Mineola, NY, USA; Figure 1B) were used
to puncture the location where the orbital vein and the sub-
mandibular vein join to form the jugular vein (Joslin, 2009). A
light pressure with dry gauze was applied to the punctured area
for hemostasis. Separation and extraction of PBMCs were per-
formed using an iodixanol mixer technique (Ford and Rickwood,
1990). Mouse PBMCs were puriﬁed from whole blood by den-
sity centrifugation (300 g at 20◦C for 30 min) using solution B
(see Table 1 for preparation) of the OptiPrepTM gradient solution
(Sigma-Aldrich, Saint-Quentin-Fallavier, France). Speciﬁcally, the
OptiPrepTM gradient solution was used to separate blood into
PBMC and plasma layers with centrifugation. The PBMC lay-
ers were then carefully removed from the tube and transferred to
a new 50 ml conical tube. The PBMCs were then washed twice
with solution B (1 min each). After another centrifugation (150 g
at 20◦C for 7 min) and two washing steps (1 min each), mouse
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FIGURE 1 | Experimental protocol for isolating human and mouse
peripheral blood mononuclear cells from whole blood. (A) Cartoon
representing the different steps for isolating human PBMC from whole
circulating blood (for full details of the method, see Blood collection and
Peripheral blood mononuclear cells Isolation in human from the Section
“Experimental Procedures”). Some elements of this ﬁgure were produced
using Servier Medical Art image bank (www.servier.com). (B) Cartoon
representing the different steps for isolating mouse PBMC from whole
circulating blood (for full details of the method, see Blood collection and
Peripheral blood mononuclear cells Isolation in mouse from the Section
“Experimental Procedures”). Some elements of this ﬁgure were produced
using Servier Medical Art image bank (www.servier.com).
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Table 1 | Solution used to prepare peripheral blood mononuclear cells from mouse whole blood.
OptiPrepTM density
gradient medium
Tricine-buffered saline (TBS) Solution B
Solutions D1556-250ML
(Sigma-Aldrich, France)
0.85% NaCl, 10 mM;Tricine-NaOH, pH 7.4
(Tricine as 100 mM stock solution at 4◦C;
1.79 g/100 ml water )
Dissolve 0.85 g NaCl in 50 ml water; add 10 ml of
Tricine stock; adjust to pH 7.4 with 1 M NaOH and
make up to 100 ml
PBMCs were recovered with a ﬁnal centrifugation (1,000 g at 4◦C
for 5 min) and were stored at −80◦C.
β-ARRESTIN 1 LEVELS IN HUMAN AND MOUSE PERIPHERAL BLOOD
MONONUCLEAR CELLS
Protein extraction from peripheral blood mononuclear cells and
immunoblots
Peripheral blood mononuclear cells were thawed and homoge-
nizedwith cell lysis buffer containing [20mMTris pH7.4, 137mM
NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA) pH 7.4,
1% Triton X-100, 25 mM β-glycerophosphate, 1 mM phenyl-
methylsulfonyl ﬂuoride (PMSF), 10 μg/ml aprotinin, 10 μg/ml
leupeptin, and 10 μg/ml pepstatin and 100 mM orthovanadate],
were incubated on ice for 20 min, were then subjected to cen-
trifugation at 21,130 g at 4◦C for 20 min. Protein concentrations
were quantiﬁed using a BCA Protein Assay Kit (Pierce Biotech-
nology).
β-Arrestin 1 level measurements with immunoblot analyses
Equal amounts of proteins were separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to polyvinylidene diﬂuoride (PVDF) membranes (Amer-
sham Biosciences, Les Ulis, France). The membranes were then
incubated overnight with a primary mouse monoclonal anti-β-
arrestin 1 antibody (#610551, BDBiosciences Pharmingen, France;
1:100). In order to ensure that equal amounts of total protein
(30 μg) were loaded in each lane, β-actin protein levels were also
assessed [β-actin (C4) horseradish peroxidase (HRP), Santa Cruz
Biotechnology, Germany, 1:10,000]. Immune complexes were
detected using appropriate peroxide-conjugated secondary anti-
bodies and a chemiluminescent reagent kit (PierceBiotechnology).
Immunoblot quantiﬁcations were performed by densitometric
scanning with Image Lab Software (Bio-Rad). Signals were in the
linear range. The densitometry values were normalized against the
β-actin values (Figures 2 and 3).
CORTICOSTERONE MODEL AND TREATMENT
The dose and duration of corticosterone treatment (CORT
model) were selected based on previous studies (David et al.,
2009; Guilloux et al., 2011; Hache et al., 2012; Rainer et al.,
2012a,b). Exposure to chronic corticosterone results in a phe-
notype that is similar to a chronic stress phenotype, including
a deterioration of the coat state and anxiety/depression-related
behaviors. At the end, a higher emotionality score is observed
(Guilloux et al., 2011). Corticosterone (35 μg/ml/day, equiva-
lent to about 5 mg/kg/day) or vehicle (0.45% β-cyclodextrin,
β-CD) were available to mice ad libitum in the drinking water in
FIGURE 2 | β-Arrestin 1 is measurable in both human and mouse
peripheral blood mononuclear cells obtained from a low collection
volume of fresh blood. Representative western blot of β-arrestin 1 levels
in PBMCs isolated either from CD14− human cells, human or naïve mouse
whole blood. In each blot, 30 μg of total protein were run. β-Actin was used
as a control.
opaque bottles. Corticosterone-treated water was changed every
3 days to prevent degradation. Group-housed mice were also
treated with the SSRI ﬂuoxetine (18 mg/kg/day) for the last
4 weeks of the experiment (see the experimental protocol on
Figure 3A).
STATISTICAL ANALYSIS
β-Arrestin 1 levels were quantiﬁed and then expressed with a scat-
terplot or as mean ± SEM normalized to vehicle levels. Data were
analyzed using Prism 6.0 software (GraphPad, La Jolla, USA).
One-way ANOVAs were used to evaluate data when appropriate.
Signiﬁcant main effects were further analyzed by Fisher’s post hoc
test. Statistical signiﬁcance was set at p < 0.05.
RESULTS
β-ARRESTIN 1 IS DETECTED IN HUMAN AND MOUSE PBMC
We ﬁrst collected blood in order to assess whether β-arrestin 1
could be detected. Single-use lancets were used for submandibu-
lar bleeding and permitted drawing of ∼0.4 ml of blood without
the use of anesthesia (Golde et al., 2005). The mouse PBMCs
were lysed and subjected to immunoblotting. A ∼55 kDa band
that corresponded to the molecular weight of β-arrestin 1 protein
was detected with a monoclonal antibody against mouse anti-β-
arrestin 1 that is known to detect human β-arrestin 1 (Avissar et al.,
2004; Matuzany-Ruban et al., 2005; Golan et al., 2013; Figure 2).
Therefore, this method of PBMC isolation from fresh mouse
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FIGURE 3 | Chronic fluoxetine treatment (18 mg/kg/day for 28
days) restored β-arrestin 1 levels in the peripheral blood mononuclear
cells from anxio/depressive mice treated with chronic corticosterone
treatment. (A) Experimental timeline used to measure β-arrestin 1 levels in
peripheral blood mononuclear cells from naïve or anxio-depressive mouse
submandibular bleeding chronically treated or not with ﬂuoxetine during 28
days (18 mg/kg/day in the drinking water). (B) Representative western blot
of β-arrestin 1 levels in peripheral blood mononuclear cells isolated from
naïve (vehicle/vehicle, V/V), corticosterone (35 μg/ml/day; corticosterone/
vehicle, C/V) or corticosterone/ﬂuoxetine (18 mg/kg/day; corticosterone/
ﬂuoxetine, C/F) mouse whole blood. In each blot, 30 μg of protein
from mouse PBMC were run. The densitometry values for each band
allowed the calculation of a ratio: optical density for β-arrestin 1/optical
density β-actin value. (C,D) Scatterplot of the individual effects (C) or bar
charts of mean ± SEM of the effects (D) of a chronic administration (28
days) treatment with ﬂuoxetine on β-arrestin 1 levels in the peripheral blood
mononuclear cells from mice treated with chronic corticosterone in com-
parison to untreated animals. Data are expressed in percentage normalized
to vehicle/vehicle expression; n = 9–10). *p < 0.05, versus control vehicle/
vehicle group.
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blood successfully permitted measurements of β-arrestin 1 lev-
els. This method can potentially be used to investigate levels of
other proteins as well. Lysates of human total PBMCs and CD14
negative PBMC fraction cells (CD14−) were used as positive con-
trols. In addition, wewere also able to detect β-arrestin 1 in human
PBMCs isolated from low fresh circulating blood volume (7.5 ml)
of healthy adult donors obtained from Etablissement Français du
Sang (Figure 2). To our knowledge, this is the ﬁrst study to detect
β-arrestin 1 in this fashion.
Next, we decided to quantify β-arrestin 1 levels in PBMCs iso-
lated from C57BL/6Ntac mice exposed to chronic corticosterone
(David et al., 2009; Rainer et al., 2012b) that was given either
alone or in combination with the SSRI ﬂuoxetine (18 mg/kg/day;
Figure 3A).
CHRONIC FLUOXETINE TREATMENT NORMALIZES β-ARRESTIN 1
EXPRESSION IN PBMC ISOLATED FROM ANXIOUS/DEPRESSIVE-LIKE
MICE
In mouse PBMCs isolated from blood of mice treated chronically
with corticosterone (35μg/ml/day),we found thatβ-arrestin 1 lev-
els were signiﬁcantly lower (−41%; 59% of expression compared
to 100% in the control group) than the levels in naïve animals
[one-way ANOVA, F(2,25) = 3.81; *p < 0.05; Figures 3C,D].
Interestingly, a 4-week treatment with the SSRI ﬂuoxetine nor-
malized these β-arrestin 1 expression levels so that they were not
signiﬁcantly different than the levels observed in naïve animals
(Figures 3C,D).
DISCUSSION
We developed a new method to assess circulating proteins such
as β-arrestin 1 through immunoblot analyses of mouse PBMCs
isolated from whole blood. We showed signiﬁcantly reduced β-
arrestin 1 levels in PBMCs from anxious/depressed mice. These
decreased β-arrestin 1 expression levels were restored to normal
levels with chronic ﬂuoxetine treatment.
PBMCs WERE ISOLATED FROM UNANESTHETIZED MICE
A recent review from Duman’s group highlighted the need to
develop a biomarker panel for depression. This biomarker panel
should proﬁle diverse peripheral factors that together will provide
a biological signature of MDD subtypes and predict treatment
response (Schmidt et al., 2011). Assessing peripheral protein levels
in PBMCs is an attractive method because PBMCs are circulating
cells that can be easily collected and monitored. Previous stud-
ies demonstrated that PBMCs can be isolated from mouse blood
to assess immunological responses (Fuss et al., 2009). However,
to our knowledge this is the ﬁrst study to collect PBMCs from
circulating blood of unanesthetized animals. Single-use lancets
were used for submandibular bleeding. This method permit-
ted PBMCs to be collected from peripheral blood circulation
in living and unanesthetized mice. Thus, submandibular bleed-
ing is a useful method to screen putative biomarkers of the
pathophysiology of mood disorders and the response to ADs.
This technique can be easily performed multiple times in the
same animals and can be used with other rodent species such
as rats.
β-ARRESTIN 1 PROTEIN LEVELS CAN BE MEASURED IN MOUSE AND
HUMAN PBMCs
We measured β-arrestin 1 protein levels to determine whether
mouse PBMCs are useful biological materials to screen biomark-
ers for MDD pathophysiology and the AD response. Over the last
decade, several G protein receptor-related genes such as β-arrestins
were found to be involved in the pathophysiology of mood disor-
ders (Schreiber andAvissar, 2004; Beaulieu et al., 2008; David et al.,
2009). Numerous data from clinical studies support the impor-
tance of measuring β-arrestin 1 levels as a peripheral biomarker
of the pathophysiology of mood disorders and predicting the AD
response (Avissar et al., 2004; Schreiber et al., 2009; Golan et al.,
2013). However, no previous study demonstrated ex vivo measure-
ments of β-arrestin 1 levels in leukocytes isolated fromwhole blood
to compare levels betweennaïve and anxious/depressed rodents. In
addition, this is the ﬁrst study to assess β-arrestin 1 by immunoblot
in human and in mouse leukocytes simultaneously by using the
same monoclonal antibody.
In the human experiments, we were able to recover PBMCs
from 7.5 ml of whole circulating blood from healthy volun-
teers. Previous studies showed that larger amounts of blood were
needed for the detection of β-arrestin 1 in human leucocytes (Avis-
sar et al., 2004; Matuzany-Ruban et al., 2005; Golan et al., 2013).
Here, 7.5 ml was sufﬁcient to acquire 30 μg of PBMC lysate for
immunoblotting (Figure 2).
Avissar et al. (2004) demonstrated that β-arrestin 1 levels were
elevated by chronic ADs in rat cortex and hippocampus. How-
ever, by contrast with their human study, they did not provide
data showing that β-arrestin 1 levels in rat PBMCs are affected
by chronic AD treatment (Avissar et al., 2004). Therefore, we also
compared β-arrestin 1 levels in PBMCs of anxious/depressed mice
before and after chronic AD treatment (Figure 3).
β-ARRESTIN 1 IS A PREDICTIVE MARKER OF THE PATHOPHYSIOLOGY
OF DEPRESSION AND THE ANTIDEPRESSANT RESPONSE
To induce an anxious/depression-related phenotype, we utilized
a chronic corticosterone treatment that results in hallmark char-
acteristics of anxiety and depression (for review, see David et al.,
2009; Mendez-David et al., 2013). In order to delineate a panel of
biomarkers of the pathophysiology and the treatment of depres-
sion, it is ﬁrst essential to screen putative candidates in a model of
anxiety/depression. β-Arrestin 1 protein levels in leukocytes were
reduced when mice were exposed to chronic corticosterone. As
found in previous human studies (Matuzany-Ruban et al., 2005;
Golan et al., 2013), these reduced β-arrestin 1 levels were alleviated
by AD treatment.
LIMITATIONS OF THE STUDY
Measuring protein levels in mouse PBMCs at several time points is
a powerful technique that can be used to reveal potential biomark-
ers for the pathophysiology of depression and the AD response.
However, this study has some limitations that must be consid-
ered when interpreting the current ﬁndings. For example, it is
important to distinguish diagnostic biomarkers from treatment
biomarkers (Schmidt et al., 2011). This study does not address
this difference. Further studies are required to assess whether
β-arrestin 1 is a reasonable biomarker for diagnostic and/or drug
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treatments. A study that compares peripheral levels of β-arrestin
1 in stressed animals before and after AD treatment could deﬁni-
tively address this question. It also may be interesting to study
whether there is a correlation between β-arrestin 1 levels and
the severity of the anxio/depressive state (Guilloux et al., 2011).
Moreover, disease conditions are most often signiﬁed by the dys-
regulation of complex biological pathways involving multiple key
factors (Dudley andButte,2009). Thus, it is unlikely thatβ-arrestin
1 alone will be a sufﬁcient diagnostic and treatment biomarker.
However, mouse PBMCs might provide useful material to screen
a panel of biomarkers and to provide biological signatures of
MDD and AD treatments. Finally, in our study, β-arrestin 1 levels
were measured using western blots, which is a semi-quantitative
method of evaluating protein levels. The development of an
enzyme-linked immunosorbent assay (ELISA) to assess β-arrestin
1 levels would provide a more quantitative method.
CONCLUSION
In this study, we demonstrated that PBMCs isolated from a small
volume of whole blood in unanesthetized mice using a sub-
mandibular bleeding method may provide a useful biological tool
to assess circulating proteins. This method will permit future
studies to screen potential biomarkers for the pathophysiology
of depression andAD responses. We also conﬁrmed that measure-
ments of β-arrestin 1 levels in PBMCs may serve as a biochemical
marker of depression in humans (Avissar et al., 2004). Overall,
we developed a powerful tool for translational studies that can
easily be used to assess proteins measurements and to provide a
biological signature of treatment response. Identiﬁcation of a bio-
logical signature could predict the effectiveness of ADs (Fuss et al.,
2009).
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